• Explore /
  • Poster
  • / First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Abstract Poster

Authors

Timothy Yap

Timothy A. Yap

The University of Texas MD Anderson Cancer Center, Houston, TX

Timothy A. Yap , Minal A. Barve , Justin F. Gainor , Colin D. Weekes , Bruno Bockorny , Yawen Ju , Ryan Faucette , Sanela Bilic , Si Tuen Lee-Hoeflich , Guochen Song , Yung Chyung , Michelle Legler , Lu Gan , Johanna C. Bendell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04291079

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS3146)

DOI

10.1200/JCO.2021.39.15_suppl.TPS3146

Abstract #

TPS3146

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: James J. Lee

First Author: Jiajian Liu

First Author: Jiajian Liu

First Author: Judy S. Wang